AstraZeneca PLC: FDA Approvals for Truqap and Ultomiris
AstraZeneca PLC announced that the U.S. Food and Drug Administration (FDA) has approved the drug Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adults with PTEN‑deficient metastatic androgen‑sensitive prostate cancer. The approval follows the CAPItello‑281 clinical trial, which demonstrated that the combination reduced the risk of radiographic disease progression compared with standard therapy.
The FDA’s decision represents the first and only targeted treatment for this specific genetic subtype of prostate cancer. The approval is expected to broaden AstraZeneca’s oncology portfolio and could impact market dynamics in the prostate cancer therapeutic segment.
In parallel, the FDA granted priority review to AstraZeneca’s drug Ultomiris for the treatment of adults with the rare kidney disease immunoglobulin A (IgA) nephropathy. The accelerated review process reflects the FDA’s assessment of the drug’s potential to address an unmet medical need in this patient population.
AstraZeneca’s financial profile shows a market capitalization of £280 815 120 000, a 52‑week high of £15 732 and a 52‑week low of £10 103. The company’s share price closed at £13 462 on 11 June 2026, trading at a price‑to‑earnings ratio of 27.1.
The approval of Truqap and the priority review of Ultomiris are likely to influence investor sentiment and could contribute to the broader movements seen in the FTSE 100. On 15 June 2026, the FTSE 100 index registered a modest decline of 0.3 % at 10 437.54, while energy stocks such as BP and Shell slipped following the announcement of a peace agreement between the United States and Iran that opened the Strait of Hormuz.
AstraZeneca’s recent regulatory milestones underscore its ongoing commitment to expanding its therapeutic offerings across multiple disease areas, including oncology and rare kidney disorders.
